@article{3911514693064872a0fbbb0bcab74d83,
title = "An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study",
abstract = "Limited data are available regarding the efficacy of nutrition support in advanced gastric cancer (AGC) patients receiving a standard second-line combination chemotherapy. The BALAST study is conducted as a prospective, multicenter observational study to evaluate the efficacy of nutrition support for patients with AGC treated with ramucirumab plus taxane as second-line treatment. As part of the routine care, patients who are malnourished or at risk of malnutrition will receive nutrition support from dietitians. We will enroll a total of 26 patients to estimate weight control rate at 12 weeks as primary end point. This study will generate valuable data reinforcing the role of nutrition support therapy for AGC patients receiving second-line chemotherapy. ",
keywords = "FAACT, PG-SGA, advanced gastric cancer, body weight loss, nutrition, nutrition counseling, taxane and ramucirumab",
author = "Takuro Mizukami and Tempei Miyaji and Yukiya Narita and Tomohiro Matsushima and Takashi Ogura and Hiromichi Miyagaki and Ryohei Kawabata and Yoshiki Horie and Takashi Kawaguchi and Kei Muro and Hiroki Hara and Takuhiro Yamaguchi and {E Nakajima}, Takako",
note = "Funding Information: This study is supported by Eli Lilly Japan K.K. T Mizukami reports grants and personal fees from Taiho Pharmaceutical, Eli Lilly Japan and Ono Pharmaceutical; and personal fees from Otsuka Pharmaceutical Factory, Asahi Kasei Pharmaceutical, Merck Biopharma, Sanofi and Takeda Pharmaceutical. T Miyaji reports grants from Eli Lilly Japan K.K. Y Narita reports personal fees from Yakult Hon-sha, Taiho, Eli Lilly and Daiichi Sankyo; grants and personal fees from Bristol Myers Squibb; and grants and personal fees from Ono Pharma. K Muro reports grants from MSD, Daiichi Sankyo, Solasia Pharma, Amgen, Pfizer and Merck Serono; grants and personal fees from Sanofi, Taiho and Ono Pharmaceutical; and personal fees from Eli Lilly, Takeda, Bristol Myers Squibb and Bayer. H Hara reports grants and personal fees from Daiichi Sankyo, Dainippon Sumitomo Pharma, Merck Biopharma, MSD, Taiho, Chugai, ONO and BMS; grants from AstraZeneca, Eisai, LSK BioPharma, Incyte, Pfizer, Boehringer-Ingelheim, Beigene and Astellas; and personal fees from Lilly, Yakult Honsha, Sanofi, Takeda and Kyowa Hakko Kirin. T Nakajima reports personal fees from Mochida Pharmaceutical, Celltrion Healthcare Japan, Merck Serono Co., Sawai Pharmaceutical Co., Bayer Yakuhin, Bristol Myers Squibb, Teijin Pharma, Pfizer Japan Inc., Novartis Japan, Yakult Honsha Co., Nipro Cogrants and Taiho Pharmaceutical Co.; grants and personal fees from Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., Sanofi K.K., Daiichi Sankyo Co., Eli Lilly Japan K.K., Nippon Kayaku Co., Ono Pharmaceutical Co., MSD K.K.; and grants from Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Eisai Co and Solasia Pharma K.K. T Matsushima, T Ogura, H Miyagaki, R Kawabata, Y Horie, T Kawaguchi and T Yamaguchi have nothing to disclose. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.. All rights reserved.",
year = "2021",
month = jul,
doi = "10.2217/fon-2021-0076",
language = "English",
volume = "17",
pages = "2431--2438",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "19",
}
